Mindpeak
Mindpeak GmbH develops AI-powered digital pathology software for cancer detection, quantification, and classification across H&E, IHC, and mIF tissue images. It sells CE-IVD certified algorithms, biomarker analysis, and clinical trial services to BioPharma companies and diagnostic laboratories globally.
- Company typePrivate
- Founded2018
- HeadquartersHamburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Mindpeak does
Mindpeak GmbH is a Hamburg, Germany-based developer of AI-powered digital pathology software for cancer detection, quantification, and classification. Founded in 2018, the company operates a platform-plus-modules architecture centered on its proprietary peakFrontier foundational AI model, which analyzes whole-slide images across H&E, immunohistochemistry (IHC), and multiplex immunofluorescence (mIF) modalities and converts tissue information into structured, quantitative outputs. The portfolio includes BioPharma-facing modules (peakDiscover for biomarker discovery, peakPredict for therapy response prediction, peakDeploy for multi-site trial deployment, peakAcademy for pathologist training) and diagnostic lab modules (peakDx, peakDissect, PhenoScout AI) organized into clinical suites for breast, PD-L1, and HER2 scoring. Mindpeak holds 11 CE-IVD certified products, ISO 13485:2016 QMS certification, and a granted patent across 17 EU member states and the UK.
Mindpeak generates revenue through three streams: AI software licensing (CE-IVD certified and RUO algorithms sold to diagnostic labs on a subscription/recurring basis), clinical trial services (biomarker analysis and companion diagnostic support for pharma), and partner integration revenue via reseller/distribution agreements with Leica Biosystems, Epredia, and Pathomation. The company serves two primary customer segments: BioPharma companies (AstraZeneca, Discovery Life Sciences, Tubulis) needing biomarker analysis for drug development and clinical trial endpoints, and diagnostic laboratories and healthcare systems (Unilabs, Intermountain Health, Charité Berlin, PathGroup, Bio Reference Labs) seeking reproducible AI-assisted cancer diagnosis. Named validation includes multi-center studies with AstraZeneca across 12 academic centers and 1,000+ breast cancer cases.
The company has scaled rapidly: its AI has supported over 50,000 patient diagnoses across 40+ labs in 20+ countries as of late 2025, up from 30,000+ diagnoses at the September 2024 Series A. The $15.3 million Series A round (September 2024) led by ZEISS Ventures and InnoVentureFund is funding US expansion via the August 2025 launch of Mindpeak Inc. in Cambridge, MA, alongside high-profile channel partnerships with Leica Biosystems (global reseller, March 2026) and Epredia (EU distributor, February 2026).
Mindpeak firmographics
Firmographics- Name
- Mindpeak
- Legal name
- Mindpeak GmbH
- Website
- https://mindpeak.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mindpeak GmbH develops AI-powered digital pathology software for cancer detection, quantification, and classification across H&E, IHC, and mIF tissue images. It sells CE-IVD certified algorithms, biomarker analysis, and clinical trial services to BioPharma companies and diagnostic laboratories globally.
- Ownership category
- akta.pro rank
Mindpeak industry classification
Industry- Product category
- Digital Pathology AI Software
- NAICS
- Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Mindpeak is headquartered
LocationHeadquarters
- HQ city
- Hamburg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Mindpeak business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- AI Software Licensing: Mindpeak licenses its CE-IVD certified AI algorithms and diagnostic software to diagnostic laboratories and healthcare providers. Products are available as both research use only (RUO) and CE-IVD certified diagnostic tools, suggesting a mix of perpetual licensing and subscription models.
- Clinical Trial Services: Mindpeak provides biomarker analysis and companion diagnostic services to pharmaceutical companies for clinical trials, supporting patient stratification and endpoint evaluation.
- Partner Integration Revenue: Revenue generated through reseller and distribution agreements with partners like Leica Biosystems, Epredia, and Pathomation who resell Mindpeak's AI solutions.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Mindpeak product offering
Product offeringCore offering
Mindpeak develops and licenses AI-based diagnostic software for the detection, quantification, and classification of cancer in digital pathology tissue images. The company sells CE-IVD certified algorithms and research-use-only tools to pharmaceutical companies (for biomarker discovery and clinical trial support) and diagnostic laboratories (for routine cancer diagnostics in breast, lung, prostate, and gastrointestinal pathology). Products are sold under the peakFrontier platform with specialized applications including peakDiscover, peakPredict, peakDeploy, peakAcademy, peakDx, peakDissect, and PhenoScout AI.
Product overview
Mindpeak is an AI-powered digital pathology company offering a platform-plus-modules architecture. The core technology is peakFrontier, a foundational AI architecture that analyzes digital pathology images (H&E, IHC, mIF) and powers specialized applications. For BioPharma, the platform includes peakDiscover (biomarker discovery), peakPredict (predictive analytics), peakDeploy (scalable deployment), peakAcademy (training), and Phenoscout AI (multiplex immunofluorescence analysis). For Diagnostic Labs, offerings include peakDx and peakDissect decision support tools, organized into diagnostic suites: Breast Suite (HER2, ER/PR), PD-L1 Suite, and HER2 Suite. The company holds 11 CE-IVD certified products and operates under ISO 13485 QMS. Mindpeak's AI supports over 40 labs globally with 18+ IMS integrations, and has enabled diagnosis for over 50,000 patients.
Differentiator
Problem solved
Functional benefit
Brands
- peakFrontier: Foundational AI architecture that analyses digital pathology images including multiplex immunofluorescence, immunohistochemistry and H&E, converting complex tissue information into structured, quantitative outputs for regulated clinical and research use.
- PhenoScout AI
- peakDiscover
- peakPredict
- peakDeploy
- peakAcademy
- peakDx
- peakDissect
- Phenoscout AI
Products and services
- peakFrontier AI Platform Foundational AI architecture that analyzes digital pathology whole-slide images including H&E, immunohistochemistry, and multiplex immunofluorescence, converting complex tissue information into structured, quantitative outputs for regulated clinical and research use. Powers the entire portfolio of specialized applications.
- peakDiscover Extracts tissue and cellular features to characterize the tumor microenvironment and identify biomarker signatures for biomarker discovery and pharmaceutical drug development.
- peakPredict Predictive AI ecosystem that analyzes tissue-based features in relation to treatment response and clinical outcomes, enabling patient stratification for targeted therapies from standard H&E images.
- peakDeploy Enables scalable deployment of AI tissue biomarker solutions across laboratory networks, supporting reproducible analysis in multi-site clinical trials and routine diagnostics.
- peakAcademy AI-native training platform supporting standardized, reproducible biomarker assessment and pathologist training programs for consistent diagnostic results across sites.
- peakDx (Breast Suite, PD-L1 Suite, HER2 Suite) CE-IVD certified diagnostic AI suite for clinical pathology including Breast Suite (HER2, ER/PR, invasive breast cancer detection), PD-L1 Suite (pan-tumor PD-L1 quantification), and HER2 Suite (including HER2-low and HER2-ultralow detection) with algorithms for breast, lung, and gastrointestinal cancer diagnostics.
- peakDissect Automated macrodissection solution using Pan-Tumor AI to ensure optimal tissue selection for genomic sequencing while preserving limited patient samples.
- PhenoScout AI Next-generation multiplex immunofluorescence analysis solution that automates phenotype identification, biomarker quantification, and spatial readouts to reduce variability and support large-scale translational studies for pharma, diagnostics, and academic research.
- Ki-67 AI Automated Ki-67 proliferation index scoring solution supporting both hotspot-scoring and global-scoring methods according to IKWG guidelines for cancer prognosis and treatment planning.
- ER/PR AI Automated estrogen receptor (ER) and progesterone receptor (PR) scoring for breast cancer diagnostics and treatment selection.
- p53 AI Automated p53 biomarker quantification for cancer diagnostics, available through the Leica Biosystems Aperio integration under the global reseller agreement.
- Mindpeak Intelligence Platform (BioPharma Services) End-to-end clinical and research services platform combining Mindpeak's AI solutions for biomarker discovery, clinical trial support, go-to-market preparation, and biomarker training for pharmaceutical partners.
- Prostate Cancer AI Solution AI solution for prostate cancer detection and diagnostics, expanding Mindpeak's diagnostic portfolio beyond breast, lung, and gastrointestinal pathology.
Companies that use Mindpeak
Customer profileNamed customers9 records
Segments2 records
Ideal customer profiles2 records
Mindpeak technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability5 records
Feature9 records
Mindpeak partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- Revolune GmbHcoreCo-exhibit partnership at AACR 2026 to showcase integrated multiplex immunofluorescence workflow combining Revolune's mIF reagents with Mindpeak's AI-powered pathology image analysis software (PhenoScout). Aims to simplify spatial biology workflows for biomarker discovery and cancer research.
- Discovery Life SciencesmajorStrategic partnership to integrate AI-powered digital pathology for biomarker analysis in global clinical trials. Collaboration combines Mindpeak's AI platform with Discovery's tissue biomarker services, including their Biomarker Academy that has trained over 6,000 pathologists and supported more than 2,000 clinical trial programs.
- Leica BiosystemsmajorGlobal reseller agreement announced March 2026. Leica Biosystems, a Danaher company and global leader in digital pathology, resells Mindpeak's AI applications within its Aperio digital pathology ecosystem. Initial offering includes nine AI applications for biomarker quantification covering Ki-67, HER2, ER/PR, p53, and PD-L1.
- EprediacoreEU distribution agreement for Mindpeak's AI-powered image recognition software in cancer diagnostics. Epredia, a subsidiary of PHC Holdings Corporation, integrates Mindpeak's technology for pixel-level analysis of digital tissue images for breast, lung, and gastrointestinal pathology diagnostics.
- TubulisminorCollaborative agreement to explore opportunities at the intersection of biotechnology and AI-driven diagnostics. Tubulis develops next-generation antibody-drug conjugates (ADCs) and Mindpeak provides AI for biomarker characterization.
- PathGroupmajorPartnership with one of the leading providers of anatomic, clinical, molecular and digital pathology services in the US. Combines Mindpeak's AI image analysis technology with PathGroup's pathologist-led network to bring AI into everyday diagnostics.
- PathomationcoreStrategic collaboration for native integration of Mindpeak's CE-IVD certified AI algorithms (Ki-67, HER2, zero-click PD-L1) into Pathomation's digital pathology platform. Pathomation's worldwide presence spans Europe, Asia, and Latin America.
- Techcyte Inc.coreMindpeak joined Techcyte's Fusion Partner Program to integrate its explainable AI tools into Techcyte's cloud-based Fusion platform, aiming to improve accuracy and transparency in pathology diagnostics.
- AstraZenecamajorMulti-center observational study in Brazil, Egypt, and Kenya evaluating AI-powered pathology tools for breast cancer diagnosis. Collaboration also includes multinational study validating AI-assisted HER2 IHC scoring across 12 academic centers and 1,000+ breast cancer cases presented at ASCO 2025 and ESMO 2025.
- AstraZenecamajorObservational study in Brazil, Egypt, and Kenya evaluating AI-powered digital pathology risk assessment tools for breast cancer diagnosis to validate AI software effectiveness in resource-limited regions.
- ZEISS MicroscopymajorPartnership to develop integrated Multiplex Immunofluorescence (mIF) solution combining ZEISS's advanced instruments with Mindpeak's AI-powered pathology analysis. Joint solution integrates both companies' offerings for enhanced value in the mIF market.
- Sagis DiagnosticsminorCollaborative study assessing the efficacy of Mindpeak's Onychomycosis AI algorithm for automated detection of hyphae from multiple slides.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Mindpeak competitors and assessment
Company assessmentDirect peers
- PathAI: Boston-based AI pathology company developing diagnostic and biomarker algorithms for pharma and clinical labs. Closely comparable to Mindpeak across BioPharma CDx services, IHC/H&E AI, and lab deployment, though operating at significantly larger scale and funding.
- Ibex Medical Analytics: Israel-based AI pathology company with CE-marked cancer diagnostic algorithms deployed across health systems. Direct overlap with Mindpeak's peakDx breast/prostate/PD-L1 suite and clinical lab GTM.
- Paige: US AI pathology company with FDA-authorized products and foundation model focus for oncology diagnostics. Direct competitor across clinical lab deployment and pharma biomarker partnerships.
- Aignostics: Berlin-based AI pathology spin-out from Charité focusing on multi-modal biomarker discovery and pharma services. Highly comparable on BioPharma GTM, foundation-model technology, and EU origin story.
- Owkin: France-based AI company deploying pathology foundation models for pharma and diagnostics. Comparable on multi-modal AI, BioPharma CDx focus, and EU regulatory positioning.
- Proscia: US digital pathology platform company that distributes third-party AI algorithms alongside its Concentriq platform. Comparable as both a potential partner and competitor to Mindpeak in lab workflows.
Emerging players
- Lunit: South Korea-based AI medical imaging company with pathology and mammography products including CE-marked and FDA-cleared diagnostics. Comparable on cancer diagnostic AI focus and clinical lab sales motion.
- Nucleai: Israel-based spatial biology AI company serving pharma with tissue-based biomarker analytics. Highly comparable to Mindpeak's PhenoScout AI and peakDiscover for pharma R&D use cases.
Broad incumbents
- Roche (Ventana Digital Pathology): Roche's diagnostics arm offers its own AI image analysis alongside the Ventana DP platform, competing and partnering across the same lab workflows Mindpeak serves.
- Philips (Digital Pathology): Philips offers IntelliSite Pathology Solution with companion AI algorithms, and Christiaan Neeleman's prior role illustrates the overlap with Mindpeak's lab deployment ambitions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Mindpeak social profiles
Digital presenceMindpeak compliance and trust
Trust signalCompliance3 records
Mindpeak financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mindpeak leadership team
Management profileNumber of profiles
Profiles7 records
Mindpeak subsidiaries and ownership
Company hierarchySubsidiaries1 record
Mindpeak funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mindpeak M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mindpeak
What does Mindpeak do?
Mindpeak develops and licenses AI-based diagnostic software for the detection, quantification, and classification of cancer in digital pathology tissue images. The company sells CE-IVD certified algorithms and research-use-only tools to pharmaceutical companies (for biomarker discovery and clinical trial support) and diagnostic laboratories (for routine cancer diagnostics in breast, lung, prostate, and gastrointestinal pathology). Products are sold under the peakFrontier platform with specialized applications including peakDiscover, peakPredict, peakDeploy, peakAcademy, peakDx, peakDissect, and PhenoScout AI.
Is Mindpeak a public or private company?
Mindpeak is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mindpeak founded?
Mindpeak was founded in 2018. It employs 11 to 50 people.
Where is Mindpeak based?
Mindpeak is headquartered in Hamburg, Germany, in the Europe region.
How does Mindpeak make money?
Three revenue lines are on record. AI Software Licensing is the primary driver. The others are clinical Trial Services and partner Integration Revenue.
Who are Mindpeak's main competitors?
Direct peers on record are PathAI, Ibex Medical Analytics, Paige, Aignostics, Owkin and Proscia. Emerging players are Lunit and Nucleai. Broad incumbents are Roche (Ventana Digital Pathology) and Philips (Digital Pathology).
Does Mindpeak have an API?
No public API is recorded for Mindpeak.
What industry is Mindpeak in?
Mindpeak's product category is Digital Pathology AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5132 and its SIC code is 7372.